Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Tracy Ju
- Phone Number: 021-68889618
- Email: TracyJu@Lanovamed.com
Study Contact Backup
- Name: Paul Kong
- Phone Number: 021-68889618
- Email: paulkong@lanovamed.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Subjects will be enrolled into the study only if they meet all of the following inclusion criteria:
- Subjects who are fully informed of the purpose, nature, method and possible adverse reactions of the study, and are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure.
- Aged ≥18 years old when sign the ICF, male or female.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1。
- Life expectancy ≥ 6 months.
- Subjects must show appropriate organ and marrow function in laboratory examinations
Exclusion Criteria:
Subjects will be excluded from the study, if they meet any of the following criteria:
- A history of other malignant tumors than multiple myeloma within 3 years prior to first dosing
- Subjects who have severe cardiovascular disease。
- Use of any live attenuated vaccines within 28 da ys prior to 1st dosing of IMP.
- Child-bearing potential female who have positive results in pregnancy test or are lactating.
- Subject who is judged as not eligible to participate in this study by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: LM-305 Dose Escalation
Administered intravenously
|
Administered intravenously
|
|
Experimental: LM-305 Combination Expansion
LM-305 Administered intravenously Dexamethasone Orally
|
Administered orally
Administered intravenously
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dose limiting toxicity (DLT)
Time Frame: Cycle 1 of each cohort. Duration of one cycle is 21 days
|
DLT is defined as a toxicity (adverse event at least possibly related to LM305) occurring during the DLT observation period
|
Cycle 1 of each cohort. Duration of one cycle is 21 days
|
|
Adverse Events (AE) and Serious Adverse Events (SAE)
Time Frame: From signing the informed consent form (ICF) until 28 days after end of treatment (EOT) or accept other anti-cancer therapy
|
The safety profile of LM-305 will be assessed by monitoring the adverse events
|
From signing the informed consent form (ICF) until 28 days after end of treatment (EOT) or accept other anti-cancer therapy
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area under plasma concentration vs time curve (AUC) for LM-305
Time Frame: Up to finished cycle 5 (each cycle is 21 days)
|
changes in AUC over time in participants with LM-305
|
Up to finished cycle 5 (each cycle is 21 days)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Depei Wu, The First Affiliated Hospital of Soochow University
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dexamethasone
Other Study ID Numbers
Other Study ID Numbers
- LM305-01-102
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.